[Specific targeting of mitomycin C to tumors with the use of anti-gastric cancer monoclonal antibody].
In the present study, an anti-gastric cancer monoclonal antibody, MGb2, was chosen to prepare antibody-mitomycin C (MMC) conjugate with dextran T-40 as intermediary. 20 molecules of MMC were introduced into each molecule of antibody, while the antigen-binding capacity of the antibody was kept well. The conjugate showed highly selective cytotoxicity upon human gastric cancer cell line SGC-7901. Radioimmunoimaging and biodistribution studies indicated that after conjugation with MMC via dextran T-40 as intermediary, the tumor localization capacity of the antibody was well retained. When tested in nude mice, by inoculation with human gastric carcinoma SGC-7901 in bilateral subrenal capsules, intraperitoneal injection of the conjugate daily for 6 days at the dose of 1 mg/kg of drug gave a tumor inhibitory rate of 68.67%, the result being far better than that of free MMC or irrelevant conjugate. No synergic effect was found in regard to the mixture of MGb2 with MMC.
Li
S
S
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D051379:Mice; D008819:Mice, Nude; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use*; D009368:Neoplasm Transplantation; D013274:Stomach Neoplasms / Q000276:immunology / Q000628:therapy*
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000922:Immunotoxins; D008937:Mitomycins; D016685:Mitomycin